Title: PAR 2 Inhibitors

Invention: This invention describes new inhibitors of the protease activated receptor 2 (PAR2), a G protein coupled receptor (GPCR) involved in inflammatory related diseases, for the treatment of asthma and a wide range of other diseases.

Background: It is estimated that by 2025 400 million people will be suffering from asthma. While the prevalence of asthma is increasing, treatments for asthma have remained constant over the past several decades. These treatments provide control for only approximately half of asthma patients. There needs to be drugs developed that allow patients to have more control over their asthma.

Applications:

• Drugs for the treatment of asthma
• Potential for use in a variety of other inflammatory diseases including chronic pain, cancer, and vascular disorders

Advantages:

• Potential to allow patients to control their allergen induced asthma

Licensing Manager:

Rakhi Gibbons
RakhiG@tla.arizona.edu
(520) 626-6695
Inventors
Josef Vagner
Associate Research Professor, BIO5 Institute
Scott Boitano
Professor, Physiology